We were originally incorporated in California in January 1992 and were
reincorporated in Delaware in May 1996.
We discover and develop innovative and life-changing pharmaceuticals, in
diseases with high unmet medical needs, through our novel R&D platform, focused
on neurological and endocrine based diseases and disorders. Our two lead
late-stage clinical programs are elagolix, a gonadotropin-releasing hormone
(GnRH) antagonist for women�s health that is partnered with AbbVie Inc.
(AbbVie), and a wholly owned vesicular monoamine transporter 2 (VMAT2) inhibitor
for the treatment of movement disorders. We intend to maintain certain
commercial rights to our VMAT2 inhibitor and evolve into a fully-integrated